We studied the prevention of experimental aortic endocarditis caused by a P-lactamase-producing, 
ampicillin plus a 3-lactamase inhibitor, sulbactam (20 mg/kg, i.v.), did not prevent the development of endocarditis in any of the animals, although mean intravegetation bacterial densities were significantly lower in animals that received vancomycin than they were in animals that received other therapies (P < 0.001). At a challenge inoculum of 106 CFU, vancomycin was 100% effective in preventing enterococcal endocarditis compared with ampicillin (29%; P < 0.00001) and ampicillin-sulbactam (65%; P < 0.01). Factors associated with the superior prophylactic efficacy of vancomycin in this model included prolonged serum inhibitory activity and time above MICs. Factors not associated with the antienterococcal prophylactic efficacy of vancomycin included the duration of the in vitro postantibiotic effect of the drug and the magnitude of the ability of this drug to enhance enterococcal in vitro opsonophagocytic killing by polymorphonuclear leukocytes. The superior prophylactic efficacy of vancomycin in this endocarditis model related to the superior pharmacokinetic profile of the drug when it was given intermittently at dose intervals of every 6 h.
Until the early 1970s, most enterococcal isolates were both moderately susceptible to penicillin and were able to be killed synergistically by combinations of penicillin plus aminoglycosides (13) . Plasmid-mediated aminoglycoside resistance has emerged widely among clinical enterococcal isolates, precluding a bactericidal synergism between cell wall-active antibiotics and aminoglycosides against such strains (4, 12) . More recently, investigators from diverse geographic areas have reported the isolation of enterococcal strains with plasmid-mediated production of both aminoglycoside-modifying enzymes as well as ,-lactamase (15) . These strains have been involved in nosocomial colonization and clinical infectious syndromes, including endocarditis (17; E. Rhinehart, C. Wennersten, E. Gorss, G. Eliopoulos, R. C. Moellering, N. Smith, and D. Goldmann, Program Abstr. 28th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 1073, 1988) . The optimal therapy for human enterococcal infections caused by aminoglycoside-resistant, ,-lactamase-producing strains is not known; similarly, the recommended prophylaxis for endocarditis caused by such strains remains undefined. Preliminary experiences in experimental endocarditis models suggest that either vancomycin or combinations of penicillin or ampicillin plus a 3-lactamase inhibitor (e.g., sulbactam or clavulanate) afford adequate efficacy against aminoglycoside-resistant, ,-lactamase-producing enterococci (7).
The current study was designed to (i) determine the role of vancomycin and the combination of ampicillin-sulbactam in preventing experimental aortic enterococcal endocarditis caused by an aminoglycoside-resistant, P-lactamase-producing strain and (ii) define the mechanism(s) involved in the (8) . The antibiotic concentrations used encompassed peak levels in serum that were achieved in pilot pharmacokinetic studies by using those dose regimens that were subsequently used in the experimental endocarditis investigation.
The fall in CFU/ml of .2 log1o units below that effected by ampicillin or sulbactam alone after 24 h of exposure to ampicillin-sulbactam was defined as evidence of an enhanced bactericidal effect of the drug combination (13) .
In vitro PAE. The presence of a persistent, sublethal postantibiotic effect (PAE) was determined for vancomycin, ampicillin, and the combination of ampicillin-sulbactam by a modification of the technique of McDonald et al. (10) . HH22 in the late logarithmic growth phase in BHI broth was diluted 1:10 in fresh BHI containing no antibiotics, vancomycin, ampicillin, or ampicillin-sulbactam to achieve (i) a final inoculum of 107 CFU/ml, (ii) final vancomycin and ampicillin concentrations 10 times the respective MICs of the drugs, and (iii) a final sulbactam concentration of 20,ug/ml. After incubation of these tubes for 2 h at 37°C, the antibiotics were removed by centrifugation of the organism at 15,000 x g for 10 min and subsequent washing of the cell pellets twice with normal saline solution (1). After washing, the cell pellets were suspended in fresh, antibiotic-free BHI broth to the original volume (20 ml) . Quantitative cultures were obtained from each tube at 0 h (preincubation), 2 and 3 h (before and after antibiotic removal, respectively), hourly for 5 h after antibiotic removal, and 15 h after antibiotic removal. Curves were then constructed relating time to viable HH22 counts.
The PAE duration (in hours) was defined as the difference in the time required for the antibiotic-exposed and unexposed HH22 cells to increase in counts by 1 log10 CFU/ml above the number present just after the centrifugation-washingresuspension step (1) . For each antibiotic regimen tested, four separate PAE experiments were performed to generate a mean + standard error of the mean PAE.
Postantibiotic leukocyte enhancement. We examined the Tubes were then centrifuged at 300 x g for 60 min. The PMN-rich layer was then drawn off into 50-ml polypropylene tubes. Contaminating erythrocytes were removed via a lysing buffer-centrifugation step. PMNs were washed twice and then suspended in Eagle minimal essential medium (MEM) with 0.1% gelatin. The PMN suspension was adjusted to a concentration of -107 cells per ml in a hemacytometer counting chamber. PMN viability was determined by trypan blue exclusion; preparations exhibiting >95% viability were used in these studies. For each experiment, freshly collected PMNs from a single donor were used.
Pooled normal human serum, which was used for opsonization of strain HH22, from five healthy donors was prepared and stored at -20°C. Pooled normal human serum was thawed on the day of use and was used at a final dilution of 10% in opsonophagocytic assays.
For assessment of postantibiotic leukocyte enhancement (PALE), HH22 was grown to the logarithmic phase, washed twice in normal saline, and suspended in MEM-gelatin to a concentration of -109 CFU/ml (optical density at 600 nm, 1.0); dilution to a final concentration of -107 CFU/ml was then performed. All washing and dilution steps were carried out at 37°C. To the bacterial-containing suspension (0.5 ml) was added 0.5 ml of either antibiotic-containing or antibioticfree MEM-gelatin for 10 min at 37°C; final antibiotic concentrations were identical to those described above for use in the PAE determinations. Previous studies have indicated that antibiotic-induced bacterial sensitization is effective by 10 min of exposure (11), while it still allows for the presence of adequate numbers of surviving organisms for assessment of PALE.
At the end of the 10-min incubation period, tubes were microcentrifuged at 10,000 rpm (22,500 x g), and the resulting cell pellet was washed twice in phosphate-buffered saline to remove residual antibiotics (dilution factor of the antibiotic[s], >1,000). Portions (0.1 ml) of antibiotic-sensitized or unsensitized HH22 cells (_107 CFU/ml) were added to 0.9-ml mixtures in MEM of PMN alone, pooled normal human serum alone, MEM alone (positive growth control), or PMN-pooled normal human serum. The final ratio of bacterial cells:PMNs in the reaction mixtures was -5:1. Assessments of the PALEs of vancomycin, ampicillin, and ampicillin-sulbactam were performed at different experimental sessions. At 0, 60, 120, and 180 min of incubation at 37°C on a rotator (10 rpm), 50-pdl portions from all reaction tubes were added to sterile distilled water to lyse PMNs. At postlysis, portions were quantitatively cultured onto sheep blood agar plates. After incubation at 37°C for 48 h, surviving HH22 colonies were counted; survival curves were then constructed in which the mean log1o CFU/ml of surviving HH22 cells in the various reaction mixtures were compared over time. For each antibiotic regimen tested, four to six separate PALE experiments were performed.
Experimental endocarditis. The experimental rabbit model was used to assess the prophylactic efficacies of the drugs against strain HH22 aortic endocarditis. One-hundred fortysix New Zealand White rabbits underwent transaortic catheterization as described previously (19) , and then 24 h later they were randomly assigned to receive either no therapy or their first prophylactic antibiotic dose. Thirty minutes after they received the first prophylactic antibiotic dose, animals were challenged intravenously (i.v.) with an inoculum of HH22 cells of either 106 or 109 CFU. It is unlikely that (20) . Heat-inactivated (56°C, 30 min), freshly pooled normal rabbit serum was used as the diluent. The strain HH22 inoculum was _105 CFU/ml. The SIT was defined as the highest serum dilution that visually inhibited turbidity after 24 h of incubation at 37°C. After determination of the SITs, 25 ,ul was subcultured from each clear well onto blood agar plates, which were incubated for 24 h for determination of the SBT.
SBT was defined as the highest serum dilution that killed >99.9% of the initial HH22 inoculum (20 In vitro PAE. Vancomycin, ampicillin, and ampicillinsulbactam did not exert a bactericidal effect against HH22 during the first 2 h of incubation (Fig. 2 ). There were no significant differences between the PAEs determined for ampicillin, vancomycin, or ampicilhin-sulbactarm ranging from 1.5 to 1.7 h.
PALE. Strain HH22, in the absence of antibiotic presensitization, was efficiently killed by PMNs via opsonophagocytic mechanisms, with a mean survival at 180 min of -40% versus the number of organisms present at 0-h inoculum; in contrast, HH22 cells were refractory to nonopsonic PMNmediated killing. Irrespective of the regimen that was used, antibiotic pretreatment resulted in an enhanced susceptibility of HH22 cells to PMN-induced opsonophagocytic killing compared with that of antibiotic-unsensitized cells (Fig. 3  and 4) . Reductions 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 various antibiotic presensitization groups. Use of decomplemented human serum abrogated the ability of PMNs to kill HH22 cells opsonophagocytically, whether or not they were presensitized.
Antibiotic pharmacokinetics in serum. The pharmacokinetics of the three antibiotic study regimens in serum are given in Table 1 . The AUCs and tj12 values were substantially greater for vancomycin than they were for ampicillin or sulbactam. Similarly, the mean time above MIC was substantially longer for vancomycin (9 h) than it was for either ampicillin or sulbactam (P < 0.01). Neither ampicillin nor sulbactam achieved supra-MBC levels postdose, while the mean time above MBC was 2 h postdose for vancomycin (Fig. 5) . For ampicillin and sulbactam, the mean peak drug levels were seen at 15 min postdose and were 31 and 34 ,ug/ml, respectively. Neither drug was detectable at trough samplings (6 h postdose).
SITs and SBTs. A comparison of the SITs induced by the three antibiotic regimens are depicted in Fig. 6 . For animals given vancomycin, SITs were .1:8 for at least 4 h postdose, with a mean reciprocal geometric titer of 38.6 + 3.9 over the 6-h postdose interval. The geometric mean reciprocal serum inhibitory activity induced by vancomycin was significantly greater than that observed with ampicillin (2.14 ± 1.23; P < 0.0001) or ampicillin-sulbactam (9.44 ± 4.1; P < 0.001). Serum inhibitory activity induced by ampicillin-sulbactam never exceeded a 1:8 titer beyond 30 min postdose, while for ampicillin alone, the serum inhibitory activity was barely measurable above a 1:2 titer at any time postdose. Similar findings were noted for SBTs (data not shown). For vancomycin, SBTs of at least 1:8 were seen in all animals for at least 120 min postdose, while for animals given ampicillinsulbactam, SBTs rarely exceeded 1:8, however, this difference in SBTs observed between the vancomycin and ampicillin-sulbactam regimens did not reach statistical significance. Ampicillin alone induced no measurable serum bactericidal activity postdose in any animals.
Prophylaxis of experimental enterococcal endocarditis. Table 2 summarizes the comparative results of the three antibiotic regimens in preventing experimental aortic enterococcal endocarditis caused by strain HH22. At the higher challenge inoculum in catheterized rabbits (-109 CFU), neither vancomycin nor ampicillin alone or with sulbactam was able to prevent the development of HH22-induced enterococcal endocarditis in any animal whether single-dose or multiple-dose prophylactic strategies were used. Of interest, mean loglo bacterial densities (±standard deviations) in vegetations from animals given vancomycin (5.24 + 2.3) were significantly lower than those from control animals or those given either ampicillin or ampicillin-sulbactam (mean log1o densities, >9.3 in each group; P<0.001).
At strain HH22 challenge inocula of -106 CFU, enterococcal endocarditis was prevented in significantly more animals given ampicillin-sulbactam by either single-dose or multiple-dose strategies (65%) than was prevented in animals given ampicillin alone (29%; P < 0.05). Vancomycin given as a single or multiple prophylactic dose regimen prevented enterococcal endocarditis in 100% of animals, a preventative rate that was significantly greater than that seen overall with either ampicillin regimen (P < 0.01).
DISCUSSION
Enterococci account for -10 to 20% of all cases of endocarditis, most of which occur on the aortic or mitral valve (9) . Among the cases of enterococcal endocarditis, -40% can be linked to a previous invasive genitourinary or gastrointestinal procedure performed within the usual incubation period of endocarditis (-2 to 6 weeks [8, 23] ). These observations have made enterococcal endocarditis a prime candidate for prophylactic antibiotic regimens in patients with underlying valvular heart disease who are undergoing invasive genitourinary or gastrointestinal procedures (22) . The recommended regimens for preventing enterococcal endocarditis in such settings have been synergistic combinations of either parenteral ampicillin or vancomycin (for penicillin-allergic patients) plus gentamicin (22) . However, the recent widespread nosocomial isolation of enterococci exhibiting plasmid-mediated, high-level resistance to aminoglycosides, with or without resistance to penicillins by virtue of ,-lactamase production, has challenged traditional prophylactic antibiotic strategies for enterococcal endocarditis.
In the present study we examined the comparative roles of vancomycin versus a combination of a P-lactam (ampicillin) and a ,-lactamase inhibitor (sulbactam) in preventing experimental aortic enterococcal endocarditis caused by an aminoglycoside-resistant, 3-lactamase-producing strain. Several findings emanated from this investigation. Neither vancomycin nor ampicillin with or without sulbactam prevented the development of endocarditis in catheterized animals challenged with a high enterococcal inoculum (109 CFU). This is in concert with this organism's in vitro inoculum effect showing increased MICs and MBCs above levels that are achievable in serum for the three antibiotics studied. It is noteworthy that, although it did not prevent the development of enterococcal endocarditis following a high-inoculum challenge, vancomycin prophylaxis was associated with a significant reduction in intravegetation bacterial densities compared with ampicillin-sulbactam regimens. This was most likely due to either a vancomycin-induced intravascular killing of enterococci contained within the initial challenge or by virtue of the prolonged serum t1/2 and serum inhibitory activity associated with vancomycin prophylaxis in comparison with those of the other antibiotic regimens that were evaluated. At a lower challenge inoculum (106 CFU), the addition of sulbactam to ampicillin significantly improved the prophylactic efficacy over that seen with ampicillin alone. However, vancomycin was universally effective at preventing enterococcal endocarditis caused by this multiresistant strain whether given by single-dose or multiple-dose strategies. These findings are in agreement with those of Ingerman et al. (7), who found that vancomycin and a 1-lactam (penicillin)-p-lactamase inhibitor (clavulanate) combination were the most effective regimens in treating established enterococcal aortic endocarditis in rats caused by a multiresistant strain similar to the one we used. The mechanism(s) by which vancomycin exerted its superior prophylactic efficacy compared with that of ampicillinsulbactam in the current study was also investigated. Glauser and colleagues (2, 6, 14) and Scheld et al. (21) have
